Basit öğe kaydını göster

The role of microsatellite instability to predict clinical benefit from irinotecan-based regimens in metastatic colorectal cancer

dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorGelen, Tekinalp
dc.contributor.authorItirli, Gülçin
dc.contributor.authorAksoy, Nazif
dc.contributor.authorÖzdoǧan, Mustafa
dc.contributor.authorSavaş, Burhan
dc.contributor.authorSamur, Mustafa
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorPehlivan, Sacide
dc.contributor.authorAkcan, Songül
dc.date.accessioned2022-02-18T11:27:02Z
dc.date.available2022-02-18T11:27:02Z
dc.date.issued2008
dc.identifier.citationArtaç M., Pehlivan S., Akcan S., Pehlivan M., Gelen T., Itirli G., Aksoy N., Özdoǧan M., Savaş B., Samur M., et al., "The role of microsatellite instability to predict clinical benefit from irinotecan-based regimens in metastatic colorectal cancer", Turkish Journal of Cancer, cilt.38, sa.2, ss.49-56, 2008
dc.identifier.othervv_1032021
dc.identifier.otherav_f9787c38-6a53-4ca4-b4a1-b7a51c267e8c
dc.identifier.urihttp://hdl.handle.net/20.500.12627/181227
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=48649096610&origin=inward
dc.description.abstractThe aim of our study was to assess the relationship between microsatellite instability (MSI) and the clinical outcome in metastatic colorectal cancer (CRC) patients treated with irinotecan-based regimens. We assessed best objective response, progression free survival (PFS) and overall survival (OAS) in relation to MSI analysis that was performed using BAT-25, BAT-26, D5S346, D2S123, D17S250 markers in normal and tumor DNA. The best objective response was significantly and negatively related with the D17S250 (an adjacent locus to p53) microsatellite marker (p=0.047). However, MSI score was not related with the best objective response (p=0.88). There was again no relationship between PFS, OAS and MSI score. In conclusion, this study allowed us to establish in a prospective study design that MSI status did not predict survival in metastatic colorectal cancer patients treated with irinotecan-based regimens.
dc.language.isoeng
dc.subjectHematology
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectHEMATOLOJİ
dc.subjectONKOLOJİ
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectTemel Bilimler
dc.subjectHealth Sciences
dc.subjectOncology
dc.subjectCancer Research
dc.subjectLife Sciences
dc.titleThe role of microsatellite instability to predict clinical benefit from irinotecan-based regimens in metastatic colorectal cancer
dc.typeMakale
dc.relation.journalTurkish Journal of Cancer
dc.contributor.departmentSelçuk Üniversitesi , ,
dc.identifier.volume38
dc.identifier.issue2
dc.identifier.startpage49
dc.identifier.endpage56
dc.contributor.firstauthorID3389148


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster